GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » EPS without NRI

LSB (LakeShore Biopharma Co) EPS without NRI : $-2.70 (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co EPS without NRI?

LakeShore Biopharma Co's earnings per share without non-recurring items for the three months ended in Sep. 2024 was $0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.70.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for LakeShore Biopharma Co's EPS without NRI or its related term are showing as below:

LSB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5.3   Med: -5.3   Max: -5.3
Current: -5.3

During the past 4 years, LakeShore Biopharma Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -5.30% per year. The lowest was -5.30% per year. And the median was -5.30% per year.

LSB's 3-Year EPS without NRI Growth Rate is ranked worse than
68.35% of 1226 companies
in the Biotechnology industry
Industry Median: 10.25 vs LSB: -5.30

LakeShore Biopharma Co's EPS (Diluted) for the three months ended in Sep. 2024 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.60.

LakeShore Biopharma Co's EPS (Basic) for the three months ended in Sep. 2024 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.60.


LakeShore Biopharma Co EPS without NRI Historical Data

The historical data trend for LakeShore Biopharma Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co EPS without NRI Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24
EPS without NRI
-3.20 -1.69 -4.32 -3.73

LakeShore Biopharma Co Quarterly Data
Mar21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Mar24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only - -1.14 -1.55 - -

Competitive Comparison of LakeShore Biopharma Co's EPS without NRI

For the Biotechnology subindustry, LakeShore Biopharma Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's PE Ratio without NRI falls into.


;
;

LakeShore Biopharma Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LakeShore Biopharma Co  (NAS:LSB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


LakeShore Biopharma Co EPS without NRI Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.